Evan Rosenbaum

Evan Rosenbaum practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Evan Rosenbaum's NPI, 1104246032, was assigned on April 17, 2014. Evan Rosenbaum graduated from Albert Einstein College of Medicine in 2014. Evan Rosenbaum's New York license number on file is 382239.

Evan Rosenbaum's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Evan Rosenbaum's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Evan Rosenbaum to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Evan Rosenbaum practices. Vendor and product names are available with a free account.

Medical oncology is Evan Rosenbaum's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Evan Rosenbaum is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Evan Rosenbaum's licenses on file in 4 states: New York, Florida, New Jersey and North Carolina.

Dmand AI lists breast cancer, lung cancer and lymphoma among the conditions Evan Rosenbaum treats.

CMS data shows 337 Medicare services from Evan Rosenbaum across 5 procedure codes in 2024, for 102 Medicare patients. Medicare paid $31,241 for them. Every service was in an office.

CMS counts 102 Medicare patients who saw Evan Rosenbaum in 2024. The largest group is 65 to 74, with 48 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Evan Rosenbaum's median patient age at 70, with 52% women.

In 2024, Evan Rosenbaum wrote 283 Medicare Part D claims for 54 patients. 81% of them were for generic drugs. CMS names the drug for 153 of them, across 9 drugs with 11 or more claims each, at $681,465 in total drug cost. In 2023, CMS named 194 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Evan Rosenbaum for performance year 2024, reported as part of a group. Evan Rosenbaum accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Evan Rosenbaum as offering telehealth.

Dmand AI links 38 papers to Evan Rosenbaum, published from 2016 to 2025. 2019 was the busiest year, with 5. The most frequent topics are Sarcoma, Antineoplastic Combined Chemotherapy Protocols and Hemangiosarcoma. Evan Rosenbaum has published most often in Clin Cancer Res. Evan Rosenbaum's most frequent co-authors are William D. Tap, MD, Ping Chi, MD, PhD and Mrinal M. Gounder, MD.

Dmand AI links Evan Rosenbaum to 4 clinical trials, 2 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Sarcoma, Neoplasms, Connective and Soft Tissue and Liposarcoma. Memorial Sloan Kettering Cancer Center sponsors the most, 4.

CMS Open Payments shows 3 general payments to Evan Rosenbaum from 3 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $35.

Evan Rosenbaum graduated from Albert Einstein College of Medicine in 2014.

Evan Rosenbaum is in network with 9 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Massachusetts. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.